---
title: "Charles River Labs: Buy Rating Reiterated as 2026 Outlook Strengthens; $235 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285867232.md"
description: "Analyst Charles Rhyee of TD Cowen has reiterated a Buy rating on Charles River Labs, maintaining a price target of $235. The positive outlook for 2026 is supported by strong demand from biotechnology clients, particularly mid-sized firms, and a solid book-to-bill ratio. Rhyee projects earnings of $11.04 for 2026, with a significant margin expansion expected. His analysis suggests the stock could trade at 19x the 2027 adjusted EPS estimate of $12.41, indicating attractive upside potential. Evercore ISI also maintains a Buy rating with a $220 price target."
datetime: "2026-05-11T01:55:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285867232.md)
  - [en](https://longbridge.com/en/news/285867232.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285867232.md)
---

# Charles River Labs: Buy Rating Reiterated as 2026 Outlook Strengthens; $235 Price Target Maintained

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Charles River Labs, retaining the price target of $235.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Charles Rhyee has given his Buy rating due to a combination of factors that underscore a strengthening outlook for Charles River Labs in the second half of 2026. He highlights robust demand from biotechnology customers, especially mid-sized firms, and notes that healthy proposal activity and a solid book-to-bill ratio in the DSA segment point to sustained revenue visibility despite some early-year cancellations that appear more like routine portfolio reshuffling than structural weakness.

Rhyee also underscores management’s reaffirmed 2026 adjusted EPS guidance and projects earnings of $11.04 for 2026, with a notable 500 basis-point expansion in operating margins in the back half of the year versus the first half. Based on his discounted cash flow analysis and the expectation that the stock can reasonably trade at 19x his 2027 adjusted EPS estimate of $12.41, he keeps his price target unchanged at $235, reinforcing his conviction that the shares offer attractive upside from current levels.

In another report released on May 8, Evercore ISI also maintained a Buy rating on the stock with a $220.00 price target.

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)

## Related News & Research

- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)